These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15115766)

  • 21. Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism.
    Popiel HA; Takeuchi T; Fujita H; Yamamoto K; Ito C; Yamane H; Muramatsu S; Toda T; Wada K; Nagai Y
    PLoS One; 2012; 7(11):e51069. PubMed ID: 23226463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin.
    Wang H; Lim PJ; Yin C; Rieckher M; Vogel BE; Monteiro MJ
    Hum Mol Genet; 2006 Mar; 15(6):1025-41. PubMed ID: 16461334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease.
    Carmichael J; Chatellier J; Woolfson A; Milstein C; Fersht AR; Rubinsztein DC
    Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9701-5. PubMed ID: 10920207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chaperones, protein aggregation, and brain protection from hypoxic/ischemic injury.
    Giffard RG; Xu L; Zhao H; Carrico W; Ouyang Y; Qiao Y; Sapolsky R; Steinberg G; Hu B; Yenari MA
    J Exp Biol; 2004 Aug; 207(Pt 18):3213-20. PubMed ID: 15299042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.
    Bett JS; Goellner GM; Woodman B; Pratt G; Rechsteiner M; Bates GP
    Hum Mol Genet; 2006 Jan; 15(1):33-44. PubMed ID: 16311253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of geldanamycin on the kinetics of chaperone-mediated renaturation of firefly luciferase in rabbit reticulocyte lysate.
    Thulasiraman V; Matts RL
    Biochemistry; 1996 Oct; 35(41):13443-50. PubMed ID: 8873613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones.
    Schulte TW; Akinaga S; Murakata T; Agatsuma T; Sugimoto S; Nakano H; Lee YS; Simen BB; Argon Y; Felts S; Toft DO; Neckers LM; Sharma SV
    Mol Endocrinol; 1999 Sep; 13(9):1435-48. PubMed ID: 10478836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol.
    Sharma SV; Agatsuma T; Nakano H
    Oncogene; 1998 May; 16(20):2639-45. PubMed ID: 9632140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation.
    Freeman W; Morton AJ
    Brain Res Bull; 2004 Mar; 63(1):45-55. PubMed ID: 15121238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.
    Nagai Y; Fujikake N; Popiel HA; Wada K
    Curr Pharm Biotechnol; 2010 Feb; 11(2):188-97. PubMed ID: 20166962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin.
    Roe SM; Prodromou C; O'Brien R; Ladbury JE; Piper PW; Pearl LH
    J Med Chem; 1999 Jan; 42(2):260-6. PubMed ID: 9925731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Huntingtin aggregation and toxicity in Huntington's disease.
    Bates G
    Lancet; 2003 May; 361(9369):1642-4. PubMed ID: 12747895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling the polyglutamine aggregation pathway in Huntington's disease: from basic studies to clinical applications.
    Sugaya K
    Subcell Biochem; 2012; 65():353-88. PubMed ID: 23225011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
    Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P
    J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
    Soga S; Neckers LM; Schulte TW; Shiotsu Y; Akasaka K; Narumi H; Agatsuma T; Ikuina Y; Murakata C; Tamaoki T; Akinaga S
    Cancer Res; 1999 Jun; 59(12):2931-8. PubMed ID: 10383157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death.
    Gong B; Lim MC; Wanderer J; Wyttenbach A; Morton AJ
    Brain Res Bull; 2008 Jan; 75(1):146-57. PubMed ID: 18158109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
    Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
    Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism.
    Wong HK; Bauer PO; Kurosawa M; Goswami A; Washizu C; Machida Y; Tosaki A; Yamada M; Knöpfel T; Nakamura T; Nukina N
    Hum Mol Genet; 2008 Oct; 17(20):3223-35. PubMed ID: 18658163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.
    Bagatell R; Paine-Murrieta GD; Taylor CW; Pulcini EJ; Akinaga S; Benjamin IJ; Whitesell L
    Clin Cancer Res; 2000 Aug; 6(8):3312-8. PubMed ID: 10955818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic regulation of molecular chaperone gene expression in polyglutamine disease.
    Huen NY; Chan HY
    Biochem Biophys Res Commun; 2005 Sep; 334(4):1074-84. PubMed ID: 16039613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.